Valuation & Multiples

What is a platform investment thesis in healthcare PE?

A platform investment thesis is the written strategic rationale a private equity firm builds around an initial acquisition, laying out the add-on pipeline, operational improvements, and exit plan that justify the platform multiple.

Reviewed by Stanislav Sukhinin, CFALast reviewed April 10, 2026

Quick answer

A platform investment thesis is the PE firm's plan for how a first acquired practice will grow into a multi-location roll-up through add-on acquisitions, usually targeting 3x to 5x EBITDA growth over a 4 to 7 year hold.

The detail

Platform deals are priced at a premium because the buyer is paying not just for the practice but for the foundation of a regional or national roll-up. A thesis usually covers four things. First, the add-on map: which sub-markets, how many clinics to buy, at what average multiple and EBITDA size. Second, operational improvements: centralizing billing, procurement, credentialing, and real estate to lift margins 200 to 500 basis points. Third, clinical expansion: adding ancillary services (imaging, specialty lines, telehealth) that were previously out of reach for a single practice. Fourth, the exit: who buys next (larger PE, strategic acquirer, IPO), at what multiple, with what timing. Sellers who become the platform can end up participating in 2 to 4x of equity value beyond the initial sale if the thesis works. It does not always work.

  • Healthcare PE platform deals typically target 3x to 5x EBITDA growth over a 4 to 7 year hold, per Bain Healthcare PE reports.

    Source: Bain & Company Healthcare PE Report

  • Add-on acquisitions in a PE platform roll-up typically close at 30 to 50 percent lower multiples than the original platform acquisition.

    Source: Pitchbook Healthcare Services

What this means for clinic owners

From Sorso

If a PE firm is pitching you as a platform, the price they offer is a discount against where they think the exit multiple lands after five years of work. Understand their thesis before you sign, because your rollover equity is worth whatever the next buyer thinks of their execution, not what the current buyer thinks of yours.

SS
Stanislav Sukhinin, CFA

Founder of Sorso. 19 years in corporate finance. Managed a $450M loan portfolio before building a fractional CFO firm exclusively for healthcare clinics.

Want to see how your practice measures up?

Take the 4-minute financial assessment. It is free, and it will show you where your practice is leaking money.